3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Breast
3
Tumor-Agnostic
1
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Conditions
Advanced Solid Tumors
1
Interventions
pembrolizumab
26
Pemetrexed
26
Cisplatin
25
Nivolumab
22
Carboplatin
16
Paclitaxel
14
Gemcitabine
12
Ipilimumab
11
tislelizumab
8
durvalumab
8
Ramucirumab
8
Docetaxel
8
talazoparib
7
Fluorouracil
7
Radiotherapy
6
Capecitabine
6
tremelimumab
5
cobimetinib
5
atezolizumab
5
adavosertib
5
Radiosurgery
5
Cyclophosphamide
5
Bevacizumab
5
olaparib
4
avelumab
4
Temozolomide
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
dalotuzumab
×
Other solid neoplasm
×
Clear all
NCT00635778
2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1
Completed
50 enrolled
32 charts